Common use of G2P Recommendation Non-Project G2P Option Clause in Contracts

G2P Recommendation Non-Project G2P Option. For any Non-Project G2P Claim in a U.S. patent which falls within the scope of inventions covered in a G2P Recommendation (“G2P Recommendation Non-Project G2P Claim”), Evogene hereby grants to Monsanto an option to receive an exclusive license to such claim as provided in this Section 3.1.6, but solely to Commercially Exploit Collaboration Hit Homologs, Special Collaboration Hits or PlaNet Gene Homologs (and only for as long as Monsanto has licenses hereunder with respect to such Collaboration Hit Homologs, Special Collaboration Hits or PlaNet Gene Homologs), in all fields of use, and solely for transgenic applications in the Monsanto Crops. For clarity, if Monsanto’s licenses hereunder to all Collaboration Hit Homologs, Special Collaboration Hits and/or PlaNet *** Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been provided separately to the Securities and Exchange Commission. Gene Homologs that are applicable to such G2P Recommendation Non-Project G2P Claim terminate prior to a U.S. patent being issued in respect of such claim, then the foregoing option shall not apply with respect to such G2P Recommendation Non-Project G2P Claim. Promptly after the issuance of any U.S. patent containing a G2P Recommendation Non-Project G2P Claim, Evogene shall notify Monsanto in writing thereof. Within one hundred and twenty (120) days of such notification, Monsanto shall notify Evogene in writing whether or not it elects to exercise its option with respect to any or all of the G2P Recommendation Non-Project G2P Claims contained in such patent. In the event that Monsanto exercises such option with respect to any G2P Recommendation Non-Project G2P Claim, then the invention claimed in such G2P Recommendation Non-Project G2P Claim shall be treated as a G2P Recommendation with respect to the license grant and royalty provisions set forth in this Agreement, including the terms hereof regarding termination of such licenses. If Monsanto does not exercise such option, then such G2P Recommendation Non-Project G2P Claim may be licensed to Third Parties, subject to the Non-Assert License.

G2P Recommendation Non-Project G2P Option. For any Non-Project G2P Claim in a U.S. patent which claim falls within the scope of inventions covered in a G2P Recommendation (“G2P Recommendation Non-Project G2P Claim”), Evogene hereby grants to Monsanto an exclusive option to receive an exclusive license to such claim as provided pursuant to the licenses for Project G2P Recommendations set forth in this Section 3.1.6Agreement, but solely to Commercially Exploit Collaboration Hit Homologs, Special Collaboration Hits or PlaNet Gene Homologs (and only for as long as Monsanto has licenses hereunder with respect to such Collaboration Hit Homologs, Special Collaboration Hits or PlaNet Gene Homologs), in all fields of use, and solely for transgenic applications in the Monsanto Crops. For clarity, It is clarified that if Monsanto’s licenses hereunder to all Collaboration Hit Homologs, Special Collaboration Hits and/or PlaNet *** Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been provided separately to the Securities and Exchange Commission. Gene Homologs that are applicable to such G2P Recommendation Non-Project G2P Claim terminate prior to a U.S. patent being issued in respect of such claim, then the foregoing option shall not apply with respect to such G2P Recommendation Non-Project G2P Claim. Promptly after the issuance The process applicable to exercising such exclusive option is as set forth below. Evogene shall notify Monsanto in writing of any U.S. patent containing a G2P Recommendation Non-Project G2P Claim, Evogene shall notify Monsanto in writing thereof. Within one hundred and twenty (120) days of such notification, notification Monsanto shall notify Evogene in writing whether or not it elects of its decision to exercise its option with respect to any or all of the G2P Recommendation Non-Project G2P Claims contained in such patent. In the event that Monsanto exercises such option with respect to any G2P Recommendation Non-Project G2P Claim, then the invention claimed in such G2P Recommendation Non-Project G2P Claim shall be treated as a Project G2P Recommendation with respect to the license grant and royalty provisions obligations set forth in this Agreement, including the terms hereof regarding to the termination of such licenses. If Monsanto does not exercise such option, then such G2P Recommendation Non-Project G2P Claim may be licensed to Third Parties, subject to the Non-Assert License. *** Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been provided separately to the Securities and Exchange Commission.

G2P Recommendation Non-Project G2P Option. For any Non-Project G2P Claim in a U.S. patent which falls within the scope of inventions covered in a G2P Recommendation (“G2P Recommendation Non-Project G2P Claim”), Evogene hereby grants to Monsanto an option to receive an exclusive license to such claim as provided in this Section 3.1.6, but solely to Commercially Exploit Collaboration Hit Homologs, Special Collaboration Hits or PlaNet Gene Homologs (and only for as long as Monsanto has licenses hereunder with respect to such Collaboration Hit Homologs, Special Collaboration Hits or PlaNet Gene Homologs), in all fields field of use, and solely for transgenic applications in the Monsanto Crops. For clarity, if Monsanto’s licenses hereunder to all Collaboration Hit Homologs, Special Collaboration Hits and/or PlaNet Gene Homologs that are applicable to such G2P Recommendation Non-Project G2P Claim terminate prior to a U.S. patent being issued in respect of such claim, then the *** Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been provided separately to the Securities and Exchange Commission. Gene Homologs that are applicable to such G2P Recommendation Non-Project G2P Claim terminate prior to a U.S. patent being issued in respect of such claim, then the foregoing option shall not apply with respect to such G2P Recommendation Non-Project G2P Claim. Promptly after the issuance of any U.S. patent containing a G2P Recommendation Non-Project G2P Claim, Evogene shall notify Monsanto in writing thereof. Within one hundred and twenty (120) days of such notification, Monsanto shall notify Evogene in writing whether or not it elects to exercise its option with respect to any or all of the G2P Recommendation Non-Project G2P Claims contained in such patent. In the event that Monsanto exercises such option with respect to any G2P Recommendation Non-Project G2P Claim, then the invention claimed in such G2P Recommendation Non-Project G2P Claim shall be treated as a G2P Recommendation with respect to the license grant and royalty provisions set forth in this Agreement, including the terms hereof regarding termination of such licenses. If Monsanto does not exercise such option, then such G2P Recommendation Non-Project G2P Claim may be licensed to Third Parties, subject to the Non-Assert License.